PreprintReviewVersion 3Preserved in Portico This version is not peer-reviewed
An In-Depth Insight into Clinical, Cellular and Molecular Factors in COVID19-Associated Cardiovascular Ailments for Identifying Novel Disease Biomarkers, Drug Targets and Clinical Management Strategies
Version 1
: Received: 10 October 2023 / Approved: 10 October 2023 / Online: 11 October 2023 (08:25:12 CEST)
Version 2
: Received: 14 December 2023 / Approved: 14 December 2023 / Online: 14 December 2023 (10:08:28 CET)
Version 3
: Received: 19 December 2023 / Approved: 20 December 2023 / Online: 20 December 2023 (10:57:30 CET)
How to cite:
Altaweel, M.; AlMusaad, A.; Alkhazmari, G.; Alrowaily, H.; AlSubaiee, M.; Husain, M.A.; Alomayrin, N.; Muaiweed, R.A.; Aleid, N.; Alarfaj, A.A.; AlMukhaylid, S.; Albahrani, Z.; Jalbani, A.A.; Iqbal, Z. An In-Depth Insight into Clinical, Cellular and Molecular Factors in COVID19-Associated Cardiovascular Ailments for Identifying Novel Disease Biomarkers, Drug Targets and Clinical Management Strategies. Preprints2023, 2023100701. https://doi.org/10.20944/preprints202310.0701.v3
Altaweel, M.; AlMusaad, A.; Alkhazmari, G.; Alrowaily, H.; AlSubaiee, M.; Husain, M.A.; Alomayrin, N.; Muaiweed, R.A.; Aleid, N.; Alarfaj, A.A.; AlMukhaylid, S.; Albahrani, Z.; Jalbani, A.A.; Iqbal, Z. An In-Depth Insight into Clinical, Cellular and Molecular Factors in COVID19-Associated Cardiovascular Ailments for Identifying Novel Disease Biomarkers, Drug Targets and Clinical Management Strategies. Preprints 2023, 2023100701. https://doi.org/10.20944/preprints202310.0701.v3
Altaweel, M.; AlMusaad, A.; Alkhazmari, G.; Alrowaily, H.; AlSubaiee, M.; Husain, M.A.; Alomayrin, N.; Muaiweed, R.A.; Aleid, N.; Alarfaj, A.A.; AlMukhaylid, S.; Albahrani, Z.; Jalbani, A.A.; Iqbal, Z. An In-Depth Insight into Clinical, Cellular and Molecular Factors in COVID19-Associated Cardiovascular Ailments for Identifying Novel Disease Biomarkers, Drug Targets and Clinical Management Strategies. Preprints2023, 2023100701. https://doi.org/10.20944/preprints202310.0701.v3
APA Style
Altaweel, M., AlMusaad, A., Alkhazmari, G., Alrowaily, H., AlSubaiee, M., Husain, M.A., Alomayrin, N., Muaiweed, R.A., Aleid, N., Alarfaj, A.A., AlMukhaylid, S., Albahrani, Z., Jalbani, A.A., & Iqbal, Z. (2023). <strong></strong>An In-Depth Insight into Clinical, Cellular and Molecular Factors in COVID19-Associated Cardiovascular Ailments for Identifying Novel Disease Biomarkers, Drug Targets and Clinical Management Strategies. Preprints. https://doi.org/10.20944/preprints202310.0701.v3
Chicago/Turabian Style
Altaweel, M., Aftab Ahmed Jalbani and Zafar Iqbal. 2023 "<strong></strong>An In-Depth Insight into Clinical, Cellular and Molecular Factors in COVID19-Associated Cardiovascular Ailments for Identifying Novel Disease Biomarkers, Drug Targets and Clinical Management Strategies" Preprints. https://doi.org/10.20944/preprints202310.0701.v3
Abstract
Background: COVID-19 was initially identified as a respiratory system disorder, but it has been discovered to interact with and influence the cardiovascular system. COVID-19-associated cardiovascular (CV) complications are common, resulting in high acute phase mortality and a large number of morbidities in the chronic phase, thus severely impacting patients' quality of life and health outcomes. Nevertheless, clinical, cellular, and molecular biological factors underlying the pathophysiology of cardiovascular complications associated with COVID-19 are poorly understood. Objective: This review investigates putative underlying clinical factors as well as cellular and molecular biological mechanisms by which COVID-19 leads to acute CV complications, including state-of-the-art genomic sequencing-based findings, assessing the long-term CV consequences of COVID-19, and aiming to shed light on developing strategies for differential diagnosis, risk prognostic stratification, prevention, and clinical management of CV sequlea in COVID-19 patients. Methods: For this purpose, a through review of literature and published data was carried out from first report of COVID-19 till October 2023 to find out a comprehensive account of clinical, cellular and molecular genetic factors underlying COVID-19-associated cardiovascular diseases. Results: We found that the relationship between COVID-19 and CV risk is complex and multifaceted. In addition to acute COVID-19 detertriuos effects, COVID-19 survivors may experience long-term CV effects. We provide a detailed account of the involvement of a large number of genomic alterations, microRNAs, and novel viral as well as host proteins in CVDs associated with COVID-19, which has helped identify some novel drug targets to treat COVID-19-related cardiovascular complications. Conclusions: The relationship between COVID-19 and CV risk is complex and multifaceted. While COVID-19 primarily affects the respiratory system, it can also significantly affect CV health. as compared to classical cardiovascular diseases, there are new clinical, cellular and molecular biological factors in CVDs related to COVID-19, that need specific diagnostic assays, prognostic stratification and treatment modules. Therefore, specail care is must taken to treat cardiovascular diseases associated with COVID-19.
Keywords
Cardiovascular diseases; COVID-19; pathophysiology; molecular pathogenesis; personalized cardiovascular medicine
Subject
Medicine and Pharmacology, Cardiac and Cardiovascular Systems
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received:
20 December 2023
Commenter:
Zafar Iqbal
Commenter's Conflict of Interests:
Author
Comment:
Dear respected:COVID-19 interacts with and influences the cardiovascular system. COVID19-associated cardiovascular (CV) complications are common, resulting in high acute phase mortality and a large number of morbidities in the chronic phase, thus severely impacting patients’ quality of life and health outcomes. Nevertheless, clinical, cellular and molecular biological factors underlying pathophysiology of cardiovascular complications associated with COVID-19 are poorly understood. This review investigates putative underlying clinical factors and cellular molecular biological mechanisms by which COVID-19 leads to acute CV complications, including state-of-the-art genomic sequencing-based findings, assessing Long-Term CV consequences of COVID-19, aiming to shed light on developing strategies for differential diagnosis, risk prognostic stratification, prevention and clinical management of CV sequel in COVID-19 patients.We found that the relationship between COVID-19 and CV risk is complex and multifaceted. COVID-19 survivors may experience long-term CV effects. These include persistent myocardial inflammation, myocardial fibrosis, cardiac dysfunction, and an increased risk of future CV events. Studies show the involvement of a large number of genomic alterations, microRNAs and novel viral as well as host proteins with CVDs, which has helped identify some novel drug targets to treat COVID-19-related cardiovascular complications.
Commenter: Zafar Iqbal
Commenter's Conflict of Interests: Author